Tissue Regeneration Therapeutics Inc. reaches final milestone of a $3.25 Million funding for development of its Mesenchymal Cell therapeutics platform

Toronto, Canada, October 17th 2014: Tissue Regeneration Therapeutics Inc. (TRT)
today announced it has completed the final milestone in a structured royalty sale
transaction with SWK Holdings Corporation. The transaction, valued at US$3.25 million,
was based on the strength of two TRT technology licenses in the family cord banking
services sector.

TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology
and its TXP family of cell therapy products. TRT has discovered the world’s richest source
of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-
inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC
platform technology are founded on the highly enriched source of these important cells
compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at
harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal
cells within the harvested population, their increased biological potential compared to cells
derived from adult tissues and their inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and its TXP cell therapy products. TRT is the only company in the
world to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities to
collaborating partner companies in the family banking, regenerative medicine and defense
sectors. Additional information is available at

About SWK Holdings Corporation
SWK Holdings Corporation (OTCQB: SWKH) (“SWK”) is a specialized finance company
with a focus on the global healthcare sector. SWK partners with ethical product marketers
and royalty holders to provide flexible financing solutions at an attractive cost of capital to
create long-term value for both SWK’s business partners and its investors. SWK believes its
financing structures achieve an optimal partnership for companies, institutions and inventors
seeking capital for expansion or capital and estate planning by allowing its partners to
monetize future cash flow with minimal dilution to their equity stakes. Additional
information on the life science finance market is available on the Company’s website

Write a comment